Johnson & Johnson's Janssen unit has agreed to offer England's National Health Service a money-back guarantee on its hep C fighter Olysio, even as the treatment won approval from the cost watchdog there.
Last week, British officials unveiled plans to toss out certain meds from the Cancer Drugs Fund, which covers drugs rejected by the country's cost-effectiveness gatekeepers. Now, the industry is calling for an overhaul in the way pricey cancer drugs are evaluated by the National Institute for Health and Care Excellence.
Gilead Sciences' hepatitis C drug Sovaldi may be worth the sticker price. But it's too expensive for the U.K.'s health system to bear. That's the assessment in some National Health Service documents obtained by the Health Service Journal.
Lundbeck has gotten a recommendation from the U.K. cost watchdog for its alcohol-addiction drug Selincro. It is estimated that there are about 600,000 potential users in the U.K. A final decision is slated for fall.
In the past, the U.K.'s cost-effectiveness gatekeeper has shown that it will bend preliminary draft guidance decisions if the price is right. But for Pfizer, which slashed costs on its targeted lung cancer drug Xalkori in hopes of gaining recommendation for its use in Britain's National Health Service, that price wasn't low enough.
Covance has formed an alliance with Royal Liverpool and Broadgreen University Hospitals NHS Trust to conduct early clinical trials for biotech and pharma clients.
In a move to generate revenue in a down economy, the U.K.'s National Health Service is planning to offer its services abroad, looking to work with international CROs, pharma companies and healthcare providers.
On the heels of news that drug spending in the U.S. rose last year, the U.K. reports a decline in its pharma costs, thanks to blockbuster medications that lost patent protection.
The U.K.'s cost-effectiveness watchdog doesn't want its advice to go unheeded. The National Institute for Health and Clinical Excellence will review National Health Service formularies, which vary
The ongoing saga of Roche's eye drug Lucentis and its involuntary competition with sister drug Avastin has taken a new turn. Regional officials with the U.K.'s National Health Service are approving